title: Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
abstract: Montelukast, a new specific oral cysteinyl LT3-receptor antagonist was evaluated for its activity in attenuating inhaled leukotriene D4 (LTD4) bronchoconstriction in patients with asthma. In two double-blind, placebo-controlled, randomized crossover studies, patients with mild asthma (forced expiratory volume in 1 second [FEV1] > or = 70%) were studied. In trial A, LTD4 challenge began 4 hours (peak plasma concentration) after a single dose of placebo or 5, 20, 100, and 250 mg montelukast. In trial B, and LTD4 challenge was started 20 hours after administration of placebo, 40 mg montelukast, or 200 mg montelukast. During each challenge, twofold increasing concentrations of LTD4 were inhaled until specific airways conductance (sGaw) decreased by at least 50% (PC50) or the highest concentration of LTD4 was inhaled. In trial A with all doses and in trial B with the 200 mg dose, bronchoconstriction was attenuated (50% fall in sGaw was not observed) up to the highest dose of LTD4 administered. In trial B, during the 40 mg period, only two of six patients exhibited a 50% fall in sGaw; PC50 ratios (montelukast 40 mg/placebo) were 18 and 45 in these two patients. These results indicate that montelukast is a highly potent and long-lasting antagonist of LTD4-induced bronchoconstriction in patients with asthma.
authors.affiliation: Merck Research Laboratories, Brussels.
authors.forename: I
authors.initials: I
authors.lastname: De Lepeleire
authors.forename: T F
authors.initials: TF
authors.lastname: Reiss
authors.forename: F
authors.initials: F
authors.lastname: Rochette
authors.forename: A
authors.initials: A
authors.lastname: Botto
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Kundu
authors.forename: M
authors.initials: M
authors.lastname: Decramer
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects*; D018592:Cross-Over Studies; D003521:Cyclopropanes; D004311:Double-Blind Method; D006801:Humans; D020024:Leukotriene Antagonists; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D018077:Receptors, Leukotriene; D013440:Sulfides; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D008565:Membrane Proteins; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor; C093875:montelukast